Literature DB >> 2855221

Alpha-2-adrenergic pathways release growth hormone via a non-GRF-dependent mechanism in normal human subjects.

R Valcavi1, C Dieguez, M D Page, M Zini, P Casoli, I Portioli, M F Scanlon.   

Abstract

Administration of a supramaximal dose of GRF 1-44 (200 micrograms, i.v.) to normal human volunteers increased GH levels while a further bolus of GRF (200 micrograms i.v.) given 2 hours later failed to increase plasma GH levels. In contrast, alpha-adrenergic receptor agonism with either propranolol-adrenaline infusion or clonidine increased plasma GH levels at a time when GH responses to this supramaximal dose of GRF were absent. This indicates that alpha-adrenergic pathways stimulate GH secretion through a non-GRF-dependent mechanism in normal human subjects.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2855221     DOI: 10.1111/j.1365-2265.1988.tb01229.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

1.  Growth hormone release during insulin tolerance, clonidine, arginine and growth hormone releasing hormone tests in short normal children and adolescents.

Authors:  L Cavallo; A Acquafredda; S Liuzzi; R Russo; C Zecchino; R Leuzzi; T Giobbe; L Piacente
Journal:  J Endocrinol Invest       Date:  1992-02       Impact factor: 4.256

2.  Role of growth hormone-releasing hormone on pentagastrin-induced growth hormone release in normal subjects.

Authors:  J F Garcia-Rojas; A Mangas; A Barba; J Millan; C Dieguez; E Zamora
Journal:  J Endocrinol Invest       Date:  1991-03       Impact factor: 4.256

Review 3.  Involvement of brain catecholamines and acetylcholine in growth hormone deficiency states. Pathophysiological, diagnostic and therapeutic implications.

Authors:  E E Müller; V Locatelli; E Ghigo; S G Cella; S Loche; C Pintor; F Camanni
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

4.  Growth rate and growth hormone response to growth hormone-releasing hormone challenge in slowly growing children during chronic administration of clonidine.

Authors:  F Orio; N Padovano; L Cinquanta; A Colao; B Merola; S Longobardi; E Rossi; V Esposito; F Orio; G Lombardi
Journal:  J Endocrinol Invest       Date:  1995-01       Impact factor: 4.256

5.  Effect of the enhancement of the cholinergic tone by pyridostigmine on the exercise-induced growth hormone release in man.

Authors:  M Cappa; A Grossi; S Benedetti; F Drago; S Loche; E Ghigo
Journal:  J Endocrinol Invest       Date:  1993-06       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.